Supreme Industries Q3 FY26 Earnings Conference Call Highlights

Supreme Industries reported a volume growth of 10% and a product value growth of approximately 3% for the first nine months of FY26. The Plastic Piping System business saw significant growth, while other segments showed varied performance. The company anticipates overall volume growth between 12% to 14% for the year and is focused on expanding value-added product offerings and capacities.

Financial Performance Overview

For the first nine months of FY26, Supreme Industries achieved a plastic goods sale of 522,018 MT, resulting in a net product turnover of ₹7,582 Crores. This compares to 474,645 MT and ₹7,336 crores in the corresponding period of the previous year. Consolidated Operating Profit stood at ₹980 crores, and Profit after Tax was ₹520 crores.

Segment Performance

The Plastic Piping System business grew by 16% in volume and 10% in value during Q3 FY26. The Packaging Product Segment grew by 2% in volume but decreased by 2% in value. The Industrial Products Segment remained flat in volume and grew by 1% in value. The Consumer Product Segment grew by 8% in volume and 5% in value.

Business Outlook and Strategy

The company anticipates overall volume growth between 12% to 14% and 15% to 17% in the Plastic Piping Business for the entire year. Capacity expansions are nearing completion and will be available for the full Fiscal Year 26-27. Capital expenditure for the first nine months amounted to ₹1,031 Crs, and total outflow for the year is expected to be around ₹1,200 Crs, funded from internal accruals.

Growth Drivers and Expansion

Supreme Industries is expanding its range of Electrofusion (EF) Fittings and bath ware products. Capacity expansions are underway, and the company expects its Plastic Piping Business capacity to reach 1 million MT per annum by FY2026. The company has fully executed an LOI for supplying composite LPG cylinders and is working to expand export geographies.

Guidance and Expectations

The company has revised its margin guidance for the current year to between 13.5% to 14%. While interest costs have temporarily increased due to funding CAPEX, they are expected to normalize from Q1 FY’27. The company aims to remain debt-free and anticipates a strong cash surplus.

Source: BSE

Previous Article

Gland Pharma Q3FY26 Results Show 22% YoY Revenue Growth

Next Article

LMW Limited Board Approves Unaudited Financial Results for Q3 2026